Healthcare / Pharmaceutical RetailersHelsinki
$0.93
-0.01 (-1.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $35.9M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$171M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-27.0%
↓Gross Margin
8.8%
↓Debt/Equity
0.69
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.4%
FCF CAGR
-6.5%
FCF margin
3.0%
FCF / Net income
-2.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.91B · net income $-27.2M · FCF $56.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.91B | $1.91B | $1.68B | $1.49B | $1.54B |
| Net Income | $-27.2M | $-27.2M | $-20.1M | $-20.7M | $-2.4M |
| EBITDA | $-6.0M | $-6.0M | $-700000.00 | $23.1M | $34.3M |
| EPS | -0.15 | -0.15 | -0.11 | -0.11 | -0.01 |
| Gross Margin | 8.8% | 8.8% | 9.6% | 10.7% | 12.1% |
| Operating Margin | 0.1% | 0.1% | 0.8% | -0.4% | 0.6% |
| Net Margin | -1.4% | -1.4% | -1.2% | -1.4% | -0.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.69 | 0.69 | 0.57 | 0.69 | 0.61 |
| Current Ratio | 0.78 | 0.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $56.7M | $56.7M | $35.9M | $6.0M | $69.4M |
| Returns | |||||
| ROE | -27.0% | -27.0% | -15.1% | -12.1% | -1.1% |
| Valuation | |||||
| EV/EBITDA | — | — | — | 8.09 | 8.64 |
| P/B | 1.69 | 1.69 | 1.29 | 1.21 | 1.42 |
| Growth & Yield | |||||
| Revenue Growth | 13.5% | 13.5% | 12.4% | -2.9% | — |
| EPS Growth | -36.4% | -36.4% | 0.0% | -1000.0% | — |
| Dividend Yield | 10.7% | 10.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.11 → -0.15
Residual
-15.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.